Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Novel Technique Improves Investigation of Interactions Between HIV and Malaria Parasite

By BiotechDaily International staff writers
Posted on 27 Aug 2012
A new video article describes a novel technique used to study the interactions between HIV-1 and Plasmodium falciparum in cultured human cells, allowing scientists to explore different parameters of coinfection by the two microbes.

Due to their extensive overlap in some developing regions, especially Sub-Saharan Africa, coinfections with malaria and HIV-1 are common, but the interplay between the two diseases is poorly understood and a systematic analysis of the interactions in different relevant human primary cell populations is critically needed. Each disease affects the immune system differently and by studying coinfection at different phases of each disease in vitro, scientists can better understand how different stages of malaria infection and HIV reproduction affect the onset and severity of the other disease.

In this study, an in vitro Plasmodium-HIV-1 coinfection model was developed and used to investigate the impact of P. falciparum-infected red blood cells on the HIV-1 replicative cycle in human primary monocyte-derived macrophages (MDMs). The impact of parasite exposure on HIV-1 transcriptional/translational events was monitored by using single cycle pseudotyped viruses in which a luciferase reporter gene has replaced the Env gene, while the effect on the quantity of progeny virus released by the infected macrophages is determined by measuring the HIV-1 capsid protein p24 by ELISA in cell supernatants. The researchers observed that exposure of P. falciparum to MDMs, decreases their susceptibility to HIV-1 infection, exerting a clear detrimental effect on the HIV-1 replicative cycle in macrophages (not excluding the possibility of other effects under different conditions).

The new technique, developed and applied by the laboratory led by Dr. David Richard of the Centre Hospitalier Universitaire de Quebec (CHUQ; Quebec City, Quebec, CA; www.chuq.qc.ca), was published August 15, 2012, in the online video Journal of Visualized Experiments (JoVE). "By publishing in JoVE, you really see what is happening in the experiment. The visual representation helps succinctly explain a long procedure, and gives you a fuller picture of the schematic complexity," said Dr. Richards. He hopes that this publication will give the scientific community an important additional tool to look at the interactions of the coinfection encounter on a cellular level and to more thoroughly dissect these interactions in a simplified system. This versatile system can also be adapted to monitor other factors and to use other primary cell types susceptible to HIV-1 infection. "Publication of the protocol in JoVE will allow researchers around the world to see a detailed demonstration of this system, which will help bring the technology to their laboratories," said JoVE editor Dr. Charlotte Frank Sage.

Related Links:

Centre Hospitalier Universitaire de Quebec
Journal of Visualized Experiments




Channels

Genomics/Proteomics

view channel
Image: Nomarski interference contrast photomicrographs of Cryptosporidium in the feces of an HIV-positive human (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).

Advanced Genetic Tools Revamp Search for Drugs to Treat Cryptosporidium

Genetically engineered modifications to genome of the diarrhea-causing parasite Cryptosporidium are expected to expedite research towards vaccine and drug development to prevent or cure infection by this pathogen.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.